A mass Murderer

n t
m e ce
of
e
g s ch
a n

n a i e t o
nd
2
a
M ateg r om i se
Ap
st r life

AIDS is no longer a death sentence for those who can get the medicines. Now its
up to the Government to create the “comprehensive strategies” to better treat the
disease.
Investigations Supportive care ARTs

History and physical Regular clinical NRTIs

examination assessments

Routine chemistry and Nutritional maintenance NNRTIs

hematology

CD4+ T lymphocyte Co trimoxazole prophylaxis Protease inhibitors

count
HIV RNA levels

Anti- Immunization HAART

Toxoplasma antibody titer
PPD skin test
  Didanosine
 Abacavir
 Lamivudine (3TC)
 Stavudine (d4T)
 Zidovudine (AZT).

Nucleoside reverse transcriptase inhibitors (NRTIs)

  Nevirapine (NVP)
 Efavirenz .

Non-Nucleoside reverse transcriptase

inhibitors (NNRTIs)
  Nelfinavir
 Amprenavir
 Saquinavir
 Indinavir
 Ritonavir

Protease inhibitors (NASIR)

Initiation - @ Category A,B,C or immune deficiency stage 2,3.

Adherence - Assessment of likelihood of adherence to treatment is

an important factor in deciding when to start therapy.

Monitoring ART S- Clinical assessment

HIV RNA levels
Viral load @ every 3-6mon
CD4 cell counts

Resistance – Due to mutations in HIV

Toxicity .
3TC
 1mon -13yrs- 4 mg/kg/dose
 >13yrs - 150 mg/kg/dose

AZT
 Neonates - 2 mg/kg/dose
 3mon-13yrs - 90-180 mg/m2

NVP
 2mon-13yrs – 120 mg/m2
 >13yrs – 200 mg – 14 days.
MTCT care
AIMED @

 Pregnant women
 Infants born to sero positive parents.
For infants born to HIV +ve
mothers
 Sd NVP + AZT – 1 week

 Delivery by elective C/S at 38 weeks before onset

of labour and rupture of membranes are to
considered.
 UN) Avoiding of Breast feeding by sero positive
mothers if replacement feeding is feasible ,
affordable.
 Early and abrupt cessation of Breast feeding.
 Take the lead

Show the way to an AIDS free life